U.S. Embolotherapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

U.S. Embolotherapy Market Trends and Growth Drivers

Shift Toward Outpatient and Ambulatory Surgical Centers Is a Key Trend

Patients are shifting toward outpatient and ambulatory surgical centers for embolotherapy treatments. This is because several players are investing in developing such centers, which offers minimally invasive procedures, cost savings, and faster recovery times, making ambulatory surgical centers the preferred option for embolization procedures.

For instance, in April 2024, Commons Clinic announced its $9.75 million investment in the Marina Orthopedic & Spine Institute (MOSI), an innovative surgery center in Los Angeles.

Rising Prevalence of Chronic Diseases Is the Growth Driver

Embolotheraphy, especially transarterial chemoembolization (TACE) and transarterial embolization (TAE) is used to treat liver cancer and other types of cancer that spread to the liver. As cancer rate is increasing, the need for embolization is growing. Also, the market is also bolstered by the rise in the demand for minimally invasive surgical technologies.

Additionally, uterine artery embolization (UAE) is now a popular treatment for women with painful uterine fibroids, a common condition in women. As more women are diagnosed with fibroids, the use of embolotheraphy as a non-surgical option is increasing.

In addition, UAE has become a popular treatment for women with painful uterine fibroids and due to this the use of embolotherapy is growing as more women are diagnosed with fibroid.

Furthermore, the advanced imaging tools and the use of artificial intelligence (AI)
are making embolotherapy procedures more accurate and precise. For instance, in July 2023, Rapid Medical announced new clinical data showing that its COMANECI embolization assists device offers significant benefits compared to traditional methods for treating ruptured wide-neck brain aneurysms.

High Cost of Embolotherapy Procedures Is a Key Challenge

The cost of embolotherapy procedures is high due the use of specialized equipments, which can be handled by professionals to ensure the quality care. Thus, professionals who performed embolotherapy procedures require specialized training in interventional radiology. As a result, the overall cost of the procedure is high for patients and healthcare providers.

U.S. Embolotherapy Market Analysis

Product Insight

• The embolic agents category held a larger market share, of around 85%, in 2024 and will grow at a higher CAGR, of 8.1%, during the forecast period.
• This is because embolic agents are increasingly used in various interventional radiological procedures.
• Furthermore, this is due to the advancements in embolic agents like drug-eluting microspheres, calibrated microspheres for non-drug-based embolization, and radioactive yttrium-90 microspheres for liver diseases.
• The increasing number of liver cancer cases is driving the demand for microspheres, which are commonly used to treat this condition.
• In 2024, according to the American Cancer Society, over 41,630 liver cancer cases were diagnosed in the U.S.

The products analyzed in this report are:

• Embolic Agents (Larger and Faster-Growing Category)
  • Microspheres
  • Embolic Coils
  • Liquid Embolic Agents
  • Embolic Plug Systems
  • Detachable Balloons
• Support Devices
  • Microcatheters
  • Guidewires

Procedure Insight

• The transcatheter arterial embolization (TAE) category held the largest market share, of around 40%, in 2024 and will grow at the highest CAGR, of 8.3%, during the forecast period.
• This is because of the increasing demand for less invasive procedures and the growing elderly population. Transcatheter arterial embolization (TAE) works well and is generally well tolerated in patients with ruptured liver cancer (HCC).
• Transcatheter arterial embolization (TAE) is effective and well-accepted by patients, and it is often preferred over other treatments like transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)/ selective internal radiation therapy (SIRT).
• Additionally, the growing demand for less invasive treatments and improvements in managing technology are expected to increase the demand for transcatheter arterial embolization (TAE).

The procedures analyzed in this report are:

• Transcatheter Arterial Embolization (TAE) (Largest and Fastest-Growing Category)
• Transarterial Radioembolization (TARE)/ Selective Internal Radiation Therapy (SIRT)
• Transarterial Chemoembolization (TACE)

Indication Insight

• The cancer category held the largest market share, of 40%, in 2024 and will grow at the highest CAGR, of 8.8%, during the forecast period.
• This is because embolization is used for the treatment of cancer including, kidney and liver cancer. It directly targets the tumor through the use of advanced imaging techniques while reducing damage to the surrounding tissue, better imaging, and stronger embolic agents have made embolization a much more effective treatment for cancer.

The indications analyzed in this report are:

• Cancer (Largest and Fastest-Growing Category)
  • Kidney
  • Liver
  • Others
• Peripheral Vascular Diseases
• Neurological Diseases
  • Cerebral Aneurysms
  • Arteriovenous Malformations & Fistulas
• Urological & Nephrological Disorders
• Gastrointestinal Disorders

End User Insight

• The hospital & clinics category held the largest market share, of 80%, in 2024 and will grow at the highest CAGR, of 8.3%, during the forecast period.
• This is because the growing use of less invasive surgeries is increasing the number of embolotherapy procedures performed in hospitals and clinics.
• Hospitals with good facilities and specialized departments like interventional radiology are preferred for embolization procedures. They also tend to have more patients than outpatient surgical centers.
• In October 2023, Sirtex Medical launched the LAVA liquid embolic system, designed specifically to treat bleeding in blood vessels outside the heart.

The end users analyzed in this report are:

• Hospital & Clinics (Largest and Fastest-Growing Category)
• Ambulatory Surgical Centers (ASCs)
• Others

U.S. Embolotherapy Market Share

• The western region in the U.S. held the largest market share, of 35%, in 2024.
• This is because western region in the U.S. has the major healthcare hubs, where there is high demand for advanced medical procedures, including embolotherapy.
• Moreover, it has a large number of specialized medical centers and access to cutting-edge healthcare technology.
• The southern region in the U.S. will grow at the highest CAGR during the forecast period.
• This is because southern region in U.S. has experienced population growth, which may lead to higher demand for medical infrastructure and advanced treatments.

The regions analyzed in this report are:

• Northeast
• Midwest
• West (Largest Category)
• South (Fastest-Growing Category)

U.S. Embolotherapy Market News

• In November 2024, Penumbra Inc. announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra’s computer-assisted vacuum thrombectomy (CAVT) technology.
• In October 2024, Merit Medical Systems announced the expansion of its maestro microcatheter product line to include a new, longer version for radial embolization procedures.
• In June 2023, Johnson & Johnson MedTech announced that its new CEREPAK detachable coils are now available in the U.S., along with the first patient cases using the product.